Adderall XR Adds 13-17 Year-Old Age Group
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA clears extended-release amphetamine for treatment of attention deficit/hyperactivity disorder in adolescents ages 13-17. Expanded indication fills gap between previous approved populations: 6-12 year-olds and adults ages 18 and older.